5 Dumbest Things on...
Health Care: Drugs
Isis Pharmaceuticals (ISIS: NASDAQ)
$20.98 0.34 | 1.65%
05/24/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ISIS | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 41.27 | 118.54 | 132.43 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 3.00 | -0.16 | -0.06 |
| Net Income | 0.87 | 0.00 | |
| EPS | -1.41 | 0.00 |
Earnings for ISIS:
| EBITDA | -68.00 |
| REVENUE | 102.05M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.27 | $-0.31 | $-0.79 | $-0.89 |
| Number of Analysts | 4 | 4 | 5 | 4 |
| High Estimate | $-0.24 | $-0.26 | $-0.28 | $-0.72 |
| Low Estimate | $-0.30 | $-0.37 | $-1.04 | $-1.07 |
| Prior Year | $-0.01 | $-0.32 | $-0.79 | $-0.79 |
| Growth Rate (Year over Year) | -2,625.00% | 3.12% | -0.51% | -11.78% |
Portfolios with ISIS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- UserCy Winther
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- UserNext Generation
- Contributor10 Biotech Stocks on Clinic...
Latest ISIS Headlines from TheStreet
- Isis Stock Falls On Unusually High Volume (ISIS) 05.08.13 | 04:05 pm
- Isis Reaches New 52-Week High (ISIS) 05.03.13 | 10:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Isis Stock Hits New 52-Week High (ISIS) 04.19.13 | 09:04 am
- Cramer's 'Mad Money' Recap: Risk vs. Reward 04.03.13 | 08:04 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- 4 Stocks Rising on Big Volume 01.31.13 | 08:01 am
- Aegerion CEO Speaks On Juxtapid Launch, Orphan Drug Pricing And Competition 01.30.13 | 06:01 am
- Isis Pharmaceuticals Stock Upgraded (ISIS) 01.28.13 | 04:01 am
- 'Mad Money' Lightning Round: I'd Buy Duke Energy 01.24.13 | 06:01 am
Press Releases for ISIS
- Roche And Isis Pharmaceuticals Form Alliance For Huntington's Disease - PR Newswire 04.08.13 | 09:04 am
- Isis Initiates Phase 1 Study Of ISIS-APOA Rx To Treat Atherosclerosis - PR Newswire 04.03.13 | 07:04 am
- Isis Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides - PR Newswire 04.01.13 | 07:04 am
- Isis Provides Update On CHMP Opinion On KYNAMROâ¿¢ (mipomersen) - PR Newswire 03.22.13 | 02:03 pm
- Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy Presented At The American Academy Of Neurology Meeting - PR Newswire 03.20.13 | 07:03 pm
- Isis Pharmaceuticals To Present At The 25th Annual ROTH Conference - PR Newswire 03.15.13 | 07:03 am
- Isis Pharmaceuticals To Host Investor Event To Discuss ISIS-SMN Rx Data Presented At 2013 AAN Annual Meeting - PR Newswire 03.14.13 | 11:03 am
- Isis Pharmaceuticals Reports Clinical Data Showing Blunting Of Severe Increases In CRP Following Endotoxin Challenge With ISIS-CRP Rx - PR Newswire 03.13.13 | 08:03 am
- Isis Pharmaceuticals To Present At The Barclays Global Healthcare Conference - PR Newswire 03.06.13 | 07:03 am
- Isis Pharmaceuticals To Present At The Cowen And Company 33rd Annual Health Care Conference - PR Newswire 02.27.13 | 07:02 am
Partner Headlines for ISIS
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Isis Pharma Issues Update on CHMP Opinion on KYNAMRO - Benzinga 03.22.13 | 02:03 pm
- Revenues Decline at Alnylam - Analyst Blog - Zacks 11.07.12 | 09:11 am
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam - Benzinga 10.23.12 | 01:10 pm
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing - Benzinga 10.16.12 | 01:10 pm
- Alnylam-ISIS Venture Prices IPO - Analyst Blog - Zacks 10.05.12 | 06:10 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - Zacks 08.22.12 | 07:08 pm
- Biogen Inks Deal with Regulus - Analyst Blog - Zacks 08.16.12 | 06:08 pm
- Pre-Market Most Active for Aug 8, 2012 : WFR, QQQ, NOK, BAC, TEF, DF, KCG, SODA, ISIS, SIRI, FB, ASML - NASDAQ 08.08.12 | 12:08 pm
